Lahore: Highnoon Laboratories Limited has reported a significant increase in its financial performance for the fiscal year ending 2024, demonstrating growth across various financial metrics. The pharmaceutical company, which operates under the guiding principle of "Enriching Life," has seen a rise in sales, earnings, and assets, according to its latest financial disclosures.

On October 15, 2024, the company announced that its sales had increased by 19.4 percent, reaching Rs. 23.20 billion compared to Rs. 19.42 billion in 2023. This growth in sales is accompanied by a 17 percent increase in profit after tax, which rose to Rs. 11.2 billion from Rs. 9.6 billion the previous year.

Earnings per share also saw a significant rise, climbing 14.5 percent to Rs. 16.06 billion from Rs. 14.03 billion in 2023. The company's equity increased by 29 percent, reaching Rs. 11.929 billion, while the total assets grew by 50.4 percent from Rs. 3.7 billion in 2021 to Rs. 5.5 billion in 2022.

According to information available from the Pakistan Stock Exchange (PSX), Highnoon Laboratories' EBITDA rose by 35 percent to Rs. 3.25 billion in 2024, up from Rs. 2.4 billion in 2023. The gross profit margin also increased by 17 percent, reflecting the company's effective management and operational efficiency.

The company's initiatives are not limited to financial growth. Highnoon Laboratories continues to engage in community programs and partnerships aimed at improving health standards and empowering individuals. Its commitment to quality and community welfare remains a core aspect of its operational strategy.

Furthermore, the distribution of value addition has seen an increase, with employee salaries, wages, and benefits rising to Rs. 3,441.35 million, up from Rs. 2,929.58 million in 2023. The company's focus on employee welfare is evident in these figures, alongside a notable increase in contributions to the Workers Profit Participation Fund.

Highnoon Laboratories also reported an increase in government contributions, with income tax, sales tax, and other levies totaling Rs. 2,052.33 million, a rise from Rs. 1,174.82 million in 2023. This reflects the company's expanding role in contributing to the national economy.

The company's financial performance is a testament to its strategic initiatives and market positioning within the designated market category of pharmaceuticals. It continues to leverage its resources and capabilities to drive growth and create value for stakeholders, aligning with its mission to enhance the quality of life through innovative healthcare solutions.